MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Bmal1 deficiency aggravates MPTP-induced dopaminergic cell death through promoting neuroinflammation

    C. Gu, W. Liu, X. Gu, F. Wang, Y. Yang, C. Liu (Su Zhou, China)

    Objective: Bmal1 is one of the most important central clock genes of circadian rhythm. Circadian rhythm dysfunction is one of the non-motor symptoms in Parkinson’s…
  • 2018 International Congress

    Characterization of the preclinical model parkinQ311X

    A. Ciammola, M. Regoni, D. Mercatelli, L. Croci, G. Serratto, S. Fasano, L. Murru, S. Novello, M. Pingue, V. Silani, G. Consalez, F. Valtorta, M. Passafaro, M. Morari, J. Sassone (Milan, Italy)

    Objective: To characterize the preclinical model parkinQ311X. Because the PARK2-associated disease in humans is characterized by juvenile onset and slow progression, in order to clarify…
  • 2018 International Congress

    Neuroprotection effects of probiotics strains on a chronic MPTP-induced mouse model of Parkinson’s disease

    Y. Qian, X. Yang, S. Xu, Q. Xiao (Shanghai, China)

    Objective: To explore the effects of probiotics strains on the neuroinflammation and degeneration of dopaminergic neurons in chronic Parkinson’s disease (PD) mice model. Background: Microglia-mediated…
  • 2018 International Congress

    Tau and α-synuclein autoantibodies as potential biomarkers for Parkinson’s and Alzheimer’s diseases

    A. Shalash, M. Salama, M. Makar, T. Roushdy, M. El-Balkimy (Cairo, Egypt)

    Objective: To investigate the value of the naturally occurring serum AIAs of α-synuclein (α-syn) and tau, proteins as potential biomarker for diagnosis of PD in…
  • 2018 International Congress

    Association between serum Vitamin D levels and Parkinson’s disease: A systematic review and meta-analysis

    XY. Luo, R. Ou, HF. Shang (Chengdu, China)

    Objective: The aim of this systematic review and meta-analysis was to evaluate the association between serum vitamin D levels and the risk and severity of…
  • 2018 International Congress

    Protective effects of Mucuna pruriens seed on rat brain: A therapeutic potential drug for Parkinson’s disease

    S. Rajput, S. Sinha (New Delhi, India)

    Objective: Objective of present study was evaluate neuroprotective and antiparkinson effects of Mp seed extract on Parkinsons brain of rats. Background: Parkinson’s disease (PD) is…
  • 2018 International Congress

    Assessment of clinical peculiarities of violations of vertical vision in patients with Parkinson’s disease

    M. Salokhiddinov, D. Akramova (Tashkent city, Uzbekistan)

    Objective: To study vertical oculomotor reflexes and the state of the functional system "eyelid" in patients with PD. Background: Parkinson's disease (PD) is a common…
  • 2018 International Congress

    Prefrontal cortical stimulation to treat anxiety and depression in Parkinson’s disease

    C. de Hemptinne, W. Chen, C. Racine, A. Seritan, A. Miller, J. Mergenthaler, S. Rajagopalan, J. Ostrem, M. San Luciano, P. Starr (San Francisco, CA, USA)

    Objective: The aims of this study are 1) to study the neurophysiology underlying anxiety and depression in PD patients, and 2) to determine whether cortical…
  • 2018 International Congress

    PrP as a receptor of alpha-synuclein in the pancreas of patients with synucleinopathies

    I. Martinez-Valbuena (Pamplona, Spain)

    Objective: We have investigated whether the cellular prion protein interacts with alpha-synuclein in pancreatic cells of patients with synucleinopathies. Background: Neurodegenerative diseases such as Alzheimer’s…
  • 2018 International Congress

    Vascular risk factors prevalence differences between Vascular Parkinsonism (VaP) and Parkinson Disease (PD) in a hospital cross-section study

    A. Velon, M. Mendes, R. Raimundo, R. Jesus, R. Almendra (Vila Real, Portugal)

    Objective: Determine and compare vascular risk factors between VaP and PD patients in a hospital-based sample. Background: Most studies demonstrate that vascular risk factors are…
  • « Previous Page
  • 1
  • …
  • 1181
  • 1182
  • 1183
  • 1184
  • 1185
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25676 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley